US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial.
Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small...
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
Global - Asia
Archived
•
October 6, 2026
•
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



